Merck Deal Activity — 40 Deals Analyzed, 2019–2026

Merck closed 40 deals between August 2019 and July 2026, committing over $45 billion in total deal value across its most recent transactions alone. The pattern is unmistakable: this is a company that knows its Keytruda patent cliff is coming and is spending accordingly. Merck's deal activity has accelerated sharply since late 2025, with mega-deals and oncology dominating the portfolio — but the company is also making significant bets in gastroenterology, infectious disease, hematology, and ophthalmology. If you're tracking merck licensing deals 2026, the signal is clear: Merck is buying scale, not just optionality.

Merck's Deal Portfolio

The concentration is striking. Oncology remains the backbone, but Merck is diversifying with real conviction — not token option deals. The tulisokibart acquisition at $11 billion for a Phase 2 gastroenterology asset signals willingness to pay premium valuations for differentiated immunology-adjacent mechanisms. The Verona Pharma deal ($10 billion TDV) and CD388 acquisition ($9.2 billion) show Merck building franchises in respiratory and infectious disease, respectively.

This is not a company nibbling at the edges. Five of the ten most recent deals exceed $2 billion in TDV. Merck is doubling down on large-scale acquisitions while maintaining a licensing pipeline for earlier-stage and ex-China assets (HS-10535, HRS-5346, CML asset). The dual approach — outright acquisitions for de-risked assets, licenses for earlier bets — is deliberate portfolio construction. Use the mega-deals benchmarks to see how these stack against sector norms.

Deal Type Preferences

Merck's preferred deal structures — license, acquisition, collaboration, option, and co-development — tell a story about a company that modulates risk appetite by stage and strategic priority.

The acquisitions cluster around Phase 2 and Phase 3 assets with near-term commercial potential: tulisokibart (Phase 2, $11B), TERN-701 (Phase 1 but with a validated CML mechanism, $6.7B), and CD388 (Phase 3, $9.2B). These are full-control moves. Merck is buying the asset, the team, and the timeline. No milestone structures, no partner alignment risk.

The licensing deals concentrate on earlier-stage or regionally sourced assets — HS-10535 and HRS-5346 both originated from Chinese biotechs and carry $2 billion TDV structures that almost certainly include significant milestone-based components. This is where Merck uses optionality to manage downside.

The collaboration with an antibody discovery partner ($838M TDV) and the ophthalmology license for EYE103 show Merck maintaining a discovery-stage funnel, but these are smaller-ticket items relative to the acquisition spree.

The 41.4% average upfront ratio across the portfolio is moderately buyer-friendly. For context, the industry average for oncology licensing deals has hovered around 25–35% upfront over the past three years. Merck's willingness to pay above-average upfront — especially on acquisitions where upfront equals TDV — reflects competitive pressure. When Merck wants an asset, they're paying to win. But on licensing deals, expect them to push milestone-heavy structures. Benchmark your own terms against Merck's patterns using the Deal Calculator.

Strategic Pattern

Three strategic threads connect Merck's deal activity over this period:

• Keytruda succession planning in oncology. The Terns Pharmaceuticals acquisition ($5.7B) and CML asset license ($838M) are pipeline-filling moves to sustain Merck's oncology franchise beyond Keytruda's LOE. TERN-701, a next-generation BCR-ABL inhibitor, gives Merck a differentiated hematology/oncology entry. These aren't defensive — they're offensive plays to maintain category leadership.
• Platform diversification beyond oncology. The tulisokibart acquisition is the clearest signal. Merck paid $11 billion — all upfront — for a Phase 2 anti-TL1A antibody in inflammatory bowel disease. This is a direct competitive move against AbbVie, Roche, and others building IL-23/TL1A franchises. The Verona Pharma acquisition ($10B) extends into respiratory. The CD388 flu deal ($9.2B) fortifies infectious disease. Merck is building a multi-franchise company, not a one-drug story.
• China-origin asset arbitrage. The HS-10535 and HRS-5346 deals — both sourced from Chinese biotechs at $2 billion TDV — continue Merck's track record of licensing differentiated molecules from China at valuations below what equivalent US-origin assets would command. This is smart capital allocation. The regulatory and geopolitical risk is real, but the pricing reflects it.

The overarching thesis: Merck is spending its Keytruda cash flows to build a diversified pharma company with leadership positions in 4–5 therapeutic areas by 2030. The deal cadence — 10 significant transactions in under 12 months — suggests the M&A team has a mandate to deploy, not to wait.

What This Means If You're Pitching to Merck

If you're a biotech founder or BD lead preparing to approach Merck, here's what the data tells you about fit and negotiation dynamics:

• Asset profile that fits: Merck is buying Phase 1–3 assets with differentiated mechanisms in oncology, immunology/inflammation, infectious disease, and respiratory. If your asset is a fast-follower with no mechanistic differentiation, Merck is not your buyer. They're paying premium for first-in-class or best-in-class candidates — tulisokibart, TERN-701, and CD388 all had clear clinical or mechanistic differentiation at the time of deal.
• Deal structure to propose: If your asset is Phase 2 or later with strong data, propose an acquisition or an exclusive license with a high upfront component. Merck has demonstrated willingness to pay 100% upfront for de-risked assets. For earlier-stage assets, propose a license with opt-in rights and a $50M–$200M upfront, benchmarked against the $838M–$2B TDV range Merck has been paying for discovery-to-Phase 1 deals. Use the Partner Matching engine to score your asset against Merck's historical preferences.
• Terms they'll push back on: Expect Merck to resist co-promote rights, retained territory carve-outs, and milestone-heavy structures where they bear development risk without control. Their recent deals overwhelmingly favor full acquisition or exclusive global licenses. If you want to retain a territory (e.g., China, Japan), you'll need to concede on upfront or accept a lower TDV. Merck's BD team is experienced and data-driven — come with comps, not aspirations.
• Timing: Merck is in active deployment mode. The pipeline urgency created by Keytruda's LOE means their willingness to pay is at a cyclical high. If your asset fits their TA focus, the next 12–18 months are likely the best negotiating window you'll have with this buyer.

Frequently Asked Questions

What therapeutic areas dominate Merck's recent deal activity?

Oncology and mega-deals dominate Merck's deal activity, but the 2025–2026 period shows significant diversification into gastroenterology, infectious disease, hematology, and respiratory. The tulisokibart ($11B), CD388 ($9.2B), and Verona Pharma ($10B) acquisitions collectively represent over $30 billion deployed outside of traditional oncology. Merck is building a multi-franchise portfolio, not just backfilling Keytruda.

What is Merck's typical deal structure and upfront ratio?

Merck uses a mix of licenses, acquisitions, collaborations, options, and co-development deals. The average upfront ratio across the portfolio is 41.4% of total deal value, which is above the industry average for large-cap pharma licensing. Notably, Merck's acquisitions (tulisokibart, TERN-701, CD388) carry 100% upfront structures, while licensing deals are more milestone-weighted. This dual approach lets Merck control high-priority assets outright while maintaining optionality on earlier bets.

How aggressive is Merck compared to other large-cap pharma acquirers?

Merck is among the most active large-cap acquirers in the 2025–2026 period, with multiple transactions exceeding $5 billion TDV in a single year. The 40-deal total across the analysis period, combined with the acceleration in deal size and frequency since late 2025, places Merck at the top of the deployment curve. The Keytruda patent cliff is the primary catalyst — Merck has both the urgency and the balance sheet to outbid competitors on high-value assets.

What does Merck's China-origin licensing activity signal?

Merck has executed multiple licensing deals for assets originating from Chinese biotechs, including HS-10535 and HRS-5346 (each $2B TDV). This signals a continued belief that China-origin molecules can offer differentiated mechanisms at lower acquisition cost than US-sourced equivalents. The geopolitical and regulatory risks are baked into the TDV structures, but Merck's persistence in this channel suggests the risk-reward calculus remains favorable for the right assets.

Ready to see how your asset matches against Merck and 850+ other potential partners? Run your profile through the Ambrosia calculator's partner matching engine — it scores therapeutic area fit, deal structure alignment, and historical upfront benchmarks in minutes, not weeks.